View : 293 Download: 0
Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia
- Title
- Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia
- Authors
- Oh, Jihoon; Oh, Jihye; Kim, Dong Wook; Youn, HyunChul; Kim, Sae-Hoon; Kim, Soo In; Chung, In Won; Wang, Kuan Shu; Kim, Minah; Paik, Jong -Woo; Koh, Min Jung; Lee, Yoosun; Choi, Seok Young; Kim, Jung-Jin
- Ewha Authors
- 김수인
- SCOPUS Author ID
- 김수인
- Issue Date
- 2023
- Journal Title
- CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE
- ISSN
- 1738-1088
2093-4327
- Citation
- CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE vol. 21, no. 2, pp. 126 - 134
- Keywords
- KEY WORDS; Schizophrenia; Antipsychotics; Paliperidone palmitate; Clinical global impression; Personal and social performance
- Publisher
- KOREAN COLL NEUROPSYCHOPHARMACOLOGY
- Indexed
- SCIE; SCOPUS; KCI
- Document Type
- Article
- Abstract
- Objective: To investigate the effects of long-acting injectable 3-monthly paliperidone palmitate on the clinical and social functioning of patients with schizophrenia. Methods: This study enrolled patients with schizophrenia receiving long-acting injectable 1-monthly paliperidone palmi-tate for at least 4 months and who subsequently received 3-monthly paliperidone palmitate. Accordingly, 418 patients were followed up for 24 weeks. Their clinical symptoms and social functioning were measured using the Clinical Global Impression-Severity of Illness and Personal and Social Performance scales. Results: The Personal and Social Performance total score was significantly higher after 3-monthly paliperidone palmitate treatment than at baseline (baseline vs. week 24: 54.3 +/- 18.0 vs. 61.0 +/- 14.5 [mean +/- standard deviation]; p < 0.001; Wilcoxon signed-rank test); the proportion of patients in the mildly ill group (scores 71-100) also increased significantly (baseline vs. week 24: 16.5% vs. 20.6%; p < 0.001; McNemar-Bowker test). The mean Clinical Global Impression-Severity of Illness score decreased significantly (baseline vs. week 24: 3.7 +/- 1.0 vs. 3.4 +/- 0.9; p < 0.001; Wilcoxon signed-rank test), as did the proportion of patients in the severely ill group (baseline vs. week 24: 4.1% vs. 2.1%; p < 0.001; McNemar-Bowker test). Conclusion: Continuous 3-monthly paliperidone palmitate treatment significantly enhances the personal and social per-formance of patients with schizophrenia and reduces the proportion of those with severe illness. These findings suggest that long-acting injectable antipsychotic administration at intervals longer than 1 month might improve the social func-tioning of and promote return to activities of daily living in patients with schizophrenia.
- DOI
- 10.9758/cpn.2023.21.1.126pISSN1738-1088/eISSN2093-4327
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML